Australia seems poised to welcome innovative medication for obesity: Retatrutide. This dual agonist – targeting on both GLP-1 and GIP receptors – demonstrates promising efficacy in international trials, suggesting substantial reductions in BMI. While approval remains with Australian regulators, a number of Australians struggling obesity could c